Table 2.
GWAS datasets for neurological and psychiatric disorders used in this study
| NPDs (abbreviation) by typea | Publication | n cases | n controls | Eff. nb | n SNPsc |
|---|---|---|---|---|---|
| Alzheimer’s disease (AD) | Jansen et al.27 | 71,880 | 383,378 | 121,062 | 9.74M |
| Amyotrophic lateral sclerosis (ALS) | Nicolas et al.28 | 20,806 | 59,804 | 30,872 | 8.85M |
| Migraine (migraine) | Gormlet et al.29 | 59,674 | 316,078 | 100,394 | 8.94M |
| Multiple sclerosis (MS) | IMSGC30 | 14,802 | 26,703 | 19,046 | 6.52M |
| Parkinson’s disease (PD) | Nalls et al.31 | 37,688 cases, 18,618 proxy cases | 1,417,791 | 108,311 | 7.52M |
| Stroke (stroke) | Malik et al.32 | 40,585 | 406,111 | 73,795 | 8.26M |
| Attention-deficit/hyperactivity disorder (ADHD) | Demontis et al.33 | 19,099 | 34,194 | 24,509 | 6.91M |
| Autism spectrum disorder (ASD) | Grove et al.34 | 18,381 | 27,969 | 22,183 | 9.11M |
| Bipolar disorder (BIP) | Stahl et al.35 | 20,352 | 31,358 | 24,684 | 9.64M |
| Major depressive disorder (MDD) | Wray et al.36 | 116,404 | 314,990 | 169,989 | 9.51M |
| Schizophrenia (SCZ) | PGC37 | 51,900 | 71,675 | 60,205 | 9.55M |
GWAS, genome-wide association study; IMSGC, International Multiple Sclerosis Genetics Consortium; NPD, neurological and psychiatric disorder; PGC, Psychiatric Genomics Consortium.
a
NPD, neurological and psychiatric disorder
b
Eff n: Effective sample size calculated from RICOPILI.38
c
SNPs with minor allele frequency < 1%.